Partnered Content

General Manager at Rentschler ATMP, Dr. Rob Panting, speaks to Scrip about his team’s critical work in cell and gene therapy.

In an exclusive interview, the CEO of Olon unveils the strategy of the Italian Group to establish itself as a competitive and cost-effective API supplier to the generics industry, combined with offering sustainable, technologically advanced manufacturing services for biopharma innovators.

Discovering and developing effective and durable treatments for cancer has long been one of the most challenging areas of medical research. Amgen is pursuing first-in-class research to transform what’s possible in cancer care.

The unmet medical need in oncology is changing. Bringing the power of immunotherapies to more patients is now the defining challenge of oncology R&D.

A commitment to supporting people has driven Zentiva through the challenges of COVID-19, and will continue to be a key feature in their strategy for continued growth moving forward.

Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.

Working with US commercial partner Supernus to file an NDA for an apomorphine infusion pump is testament to how Germany’s STADA Arzneimittel is increasingly a go-to-partner for specialty pharmaceuticals, as well as generics and consumer healthcare products.

Discusses KRAS G12C and the importance of biomarker testing in non-small cell lung cancer (NSCLC).